Retinoids for the management of dermatological complications of organ transplantation

BioDrugs

Volumn 8, Issue 3, 1997, Pages 176-184

  Euvrard, Sylvie ^a   Kanitakis, Jean ^a   Thivolet, Jean ^a   Claudy, Alain ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; ETRETIN; ETRETINATE; IMMUNOSUPPRESSIVE AGENT; ISOTRETINOIN; PREDNISOLONE; RETINOIC ACID; RETINOID;

ACNE; CHEILITIS; DRUG EFFICACY; DRUG SAFETY; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RELAPSE; REVIEW; SIDE EFFECT; SKIN CANCER; SKIN DEFECT; THROMBOCYTOPENIA; XEROSIS;

EID: 0030873104     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199708030-00003     Document Type: Review

References (77)

1. Cecka JM, Terasaki PI. Clinical transplant 1995. Los Angeles: UCLA Tissue Typing Laboratory. 1995
2. Ramos HC, Reyes J, Abu-Elmagd K. et al. Weaning of immunosuppression in long-term liver transplant patients. Transplantation 1995; 59: 212-7
3. Hartevelt MM, Bouwes-Bavinck JN, Koote AMM. et al. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990; 49: 506-9
4. Penn I. Malignant melanoma in organ allograft recipients. Transplantation 1996; 61: 274-8
5. Hardie IR, Strong RW, Harley LCJ. et al. Skin cancer in Caucasian renal allograft recipients living in a subtropical climate. Surgery 1980; 87: 177-83
6. Blohme I, Larkö O. Premalignant and malignant skin lesions in renal transplant patients. Transplantation 1984; 37: 165-7
7. Sheil AGR. Development of malignancy following renal transplantation in Australia and New Zealand. Transplant Proc 1992; 24: 1275-9
8. Walder BK, Robertson MR, Jeremy D. Skin cancer and immunosuppression. Lancet 1971; II: 1282-3
9. Penn I. Tumors alter renal and cardiac transplantation. Hematol Oncol Clin North Am 1993; 7: 431-45
10. Euvrard S, Kanitakis J, Pouteil-Noble C. et al. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J Am Acad Dermatol 1995; 33: 222-9
11. Gupta AK, Cardella CJ, Hubermann HF. Cutaneous malignant neoplasms in patients with renal transplants. Arch Dermatol 1986; 122: 1288-93
12. Levy M, Backman L, Husberg B. et al. De novo malignancy following liver transplantation, a single-center study. Transplant Proc 1993; 25: 1397-9
13. Espana A, Redondo P, Fernandez AL. et al. Skin cancer in heart transplant recipients. J Am Acad Dermatol 1995; 32: 458-65
14. Euvrard S, Kanitakis J, Pouteil-Noble C. et al. Aggressive squamous cell carcinomas in organ transplant recipients. Transplant Proc 1995; 27: 1767-8
15. Bouwes-Bavinck JN, De Boer A, Vermeer BJ. et al. Sunlight, keratotic skin lesions and skin cancer in renal transplant recipients. Br J Dermatol 1993; 129: 242-9
16. Kelly G, Scheibner A, Murray J. et al. T6+ and HLA-DR+ cell numbers in epidermis of immunosuppressed renal transplant recipients. J Cutan Pathol 1987; 14: 202-6
17. Servitje O, Seron D, Ferrer I. et al. Quantitative and morphometric analysis of Langerhans cells in non-exposed skin in renal transplant patients. J Cutan Pathol 1991; 18: 106-11
18. Smith SE, Davis IC, Leshin B. et al. Absence of human papillomavirus in squamouscell carcinomas of nongenital skin from immunocompromised renal transplant patients. Arch Dermatol 1993; 129: 1585-8
19. Barr BBB, Benton EC, McLaren K. et al. Human papillomavirus infection and skin cancer in renal allograft recipients. Lancet 1989; I: 124-9
20. Euvrard S, Chardonnet Y, Pouteil-Noble C. et al. Association of skin malignancies with various and multiple carcinogenic and non carcinogenic human papillomaviruses in renal transplant recipients. Cancer 1993; 72: 2198-206
21. Shamanin V, Zur Hausen H, Lavergne D. et al. Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J Natl Cancer Inst 1996; 88: 802-11
22. de Jong-Tieben LM, Berkhout RJM, Smits HL. et al. High frequency of detection of epidermodysplasia verruciformis-associated human papillomavirus DNA in biopsies from malignant and pre-malignant skin lesions from renal transplant recipients. J Invest Dermatol 1995; 105: 367-71
23. Berkhout RJM, Tieben LM, Smits HL. et al. Nested PCR approach for detection and typing of epidermodysplasia verruciformis-associated human papillomavirus types in cutaneous cancers from renal transplant recipients. J Clin Microbiol 1995; 33: 690-5
24. Lennard L, Thomas MJ, Hurrington CL. et al. Skin cancer in renal transplant patients is associated with increased concentrations of 6-thioguanine nucleotide in red blood cells. Br J Dermatol 1985; 113: 723-9
25. Chocair PR, Duley JA, Simmonds HA. et al. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 1992; 53: 1051-6
26. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995; 131: 193-7
27. Bouwes-Bavinck JN, Vermeer BJ, Van der Woude FJ. et al. Relation between skin cancer and HLA antigens in renal transplant recipients. N Engl J Med 1991; 325: 843-8
28. Bouwes-Bavinck JN, Hardie D, Green A. et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. Transplantation 1996; 61: 715-21
29. Czarnecki D, Watkins F, Leahy S. et al. Skin cancers and HLA frequencies in renal transplant recipients. Clin Lab Invest 1992; 185: 9-11
30. Bouwes-Bavinck JN, Gissmann L, Claas F. et al. Relation between skin cancer, humoral responses to human papillomaviruses, and HLA class II molecules in renal transplant recipients. J Immunol 1993; 151: 1579-86
31. Van Zuuren EJ, Posma AN, Scholtens REM. et al. Resurfacing the back of the hand as treatment and prevention of multiple skin cancers in kidney transplant recipients. J Am Acad Dermatol 1994; 31: 760-4
32. Bencini PL, Montagnino G, De Vecchi G. et al. Cutaneous manifestations in renal transplant recipients. Nephron 1983; 34: 79-83
33. DiGiovanna JJ. Retinoids for the future: oncology. J Am Acad Dermatol 1992; 27: S34-7
34. Bollag W, Holdener E. Retinoids in cancer prevention and therapy. Ann Oncol 1992; 3: 513
35. Lippman SM, Parkinson DR, Itri LM. et al. 13-cis-retinoic acid and Interferon α-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992; 84: 235-41
36. Lippman SM, Kavanagh JJ, Paredes-Espinoza M. et al. 13-cis-retinoic acid plus Interferon α-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992; 84: 241-5
37. Claudy AL, Rouchouse B. Treatment of cutaneous T-cell lymphomas with retinoids. In: Saurat JH. editor. Retinoids: new trends in research and therapy. Basel: Karger. 1985: 335-40
38. Moriarty M, Dunn J, Darragh A. et al Etretinate treatment of actinic keratosis. Lancet 1982; I: 364-5
39. Hong WK, Endicott J, Itri LM. et al. 12-cis retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986; 315: 1501-5
40. Schnitzler L. Rétinoïdes et prévention des épithéliomas cutanés: 1977-1987. Ann Dermatol Venereol 1987; 114: 1537-43
41. Kraemer KH, DiGiovanna JJ, Moshell AN. et al. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318: 1633-7
42. Peck G, DiGiovanna JJ, Sarnoff DS. et al. Treatment and prevention of basal cell carcinoma with oral isotretinoin. J Am Acad Dermatol 1988; 19: 176-85
43. Hong WK, Lippman SM, Itri LM. et al. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 1990; 323: 795-801
44. Lutzner MA, Blanchet-Bardon C. Oral retinoids treatment of human papillomavirus type 5-induced epidermodysplasia verruciformis. N Engl J Med 1980; 302: 1091
45. Majewski S, Jablonska S. Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin. Arch Dermatol 1995; 131: 1312-8
46. Lyons F, Laker MF, Marsden JR. et al. Effect of oral 13-cis retinoic acid on serum lipids. Br J Dermatol 1982; 197: 591-5
47. Elis CN, Swanson NA, Grekin RC. et al. Etretinate therapy causes increases in lipids levels in patients with psoriasis. Arch Dermatol 1982; 118: 559-62
48. Bershad S, Rubinstein A, Paterniti JR. et al. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med 1985; 313: 981-5
49. McGuire J, Milstone L, Lawson J. Isotretinoin administration alters juvenile and adult bone. In: Saurat JH. editor. Retinoids: new trends in research and therapy. Basel: Karger, 1985: 419-39
50. DiGiovanna JJ, Helfgott RK, Gerber LH. et al. Extraspinal tendon and ligament calcification associated with long-term therapy with etretinate. N Engl J Med 1986; 315: 177
51. Tangrea JA, Edwards BK, Taylor PR. et al. Long term therapy with low dose isotretinoin for prevention of basal cell carcinoma: amulticenterclinical trial. J Natl Cancer Inst 1992; 84: 328
52. Mork NJ, Kolbenstvedt A, Austad J. Efficacy and skeletal side effects of two years acitretin treatment. Acta Derm Venereol 1992; 72: 445-8
53. Bartsch D, Boye B, Baust C. et al. Retinoic acid mediated repression of human papillomavirus 18 transcription and different ligand regulation of the retinoic acid receptor beta gene in non-tumorigenic and lumorigenic Hela hybrid cells. EMBO J 1992; 11: 2283-91
54. Khan MA, Jenkins GR, Tolleson WH. et al. Retinoic acid inhibition of human papillomavirus type 16-mediated transformation of human keratinocytes. Cancer Res 1993; 53: 903-9
55. Floersheim GL, Bollags W. Accelerated rejection of skin homografts by vitamin A acid. Transplantation 1972; 14: 564-7
56. Fulton RA, Souteyrand P, Thivolet J. Influence of retinoids Ro 10-9359 on cell-mediated immunity in vivo. Dermatologica 1982; 165: 568-72
57. McKerrow KJ, MacKie RM, Lesko MJ. et al. The effect of oral retinoid therapy on the normal human immune system. Br J Dermatol 1988; 119: 313-20
58. Shuttleworth D, Marks R, Griffin PJA. et al. Treatment of cutaneous neoplasia with etretinate in renal transplant recipients. QJ Med 1988; 68: 717-25
59. Kelly JW, Sabto J, Gurr FW. et al. Retinoids to prevent skin cancer in organ transplant recipients. Lancet 1991; 338: 1407
60. McLelland J, Chu AC. Skin tumours in renal allograft recipients. JR Soc Med 1988; 82: 110-1
61. Glover MT, Niranjan N, Kwan JTC. et al. Non-melanoma skin cancer in renal transplant recipients: the extent of the problem and a strategy for management. Br J Plast Surg 1994; 47: 86-9
62. Rook AH, Jaworsky C, Nguyen T. et al. Beneficial effect of low-dose systemic retinoid in combination with topical tretinoin for the treatment and prophylaxis of premalignant and malignant skin lesions in renal transplant recipients. Transplantation 1995; 59: 714-9
63. Vandeghinste N, de Bersaques J, Geerts ML. et al. Acitretin as cancel chemoprophylaxis in a renal transplant recipient. Dermatology 1992; 185: 307-8
64. Bouwes-Bavinck JN, Tiehen LM, Van der Woude FJ. et al. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients, a dou- ble-blind. placebo-controlled study. J Clin Oncol 1995; 13: 1933-8
65. Yuan ZF, Davis A, MacDonald K. et al. Use of acitretin for the skin complications in renal transplant recipients. NZ Med J 1995; 108: 255-6
66. Euvrard S, Pouteil-Noble C, Kanitakis J. et al. Successive occurrence of T-cell and B-cell lymphomas alter renal transplantation in a patient with multiple cutaneous squamous cell carcinomas. N Engl J Med 1992; 327: 1924-7
67. Bellman BA, Eaglstein WH, Miller J. Low dose isotretinoin in the prophylaxis of skin cancer in renal transplant patients. Transplantation 1996; 61: 173
68. Magnone M, Holley J, Shapiro R. et al. Interferon-α induced acute renal allograft rejection. Transplantation 1994; 59: 10168-70
69. de Lacharrière O, Escoffier C, Gracia AM. et al. Reversal effects of topical retinoic acid on the skin of kidney transplant recipients under systemic corticotherapy. J Invest Dermatol 1990; 95: 516-22
70. Halliday GM, Dickinson JL, Muller HK. Retinoic acid protects Langerhans cells from the effects of the tumour promotor 12-O-tetradecanoylphorbol 13-acetate. Immunology 1989; 67: 298-302
71. Peck G. Topical tretinoin in actinic keratosis and basal cell carcinoma. J Am Acad Dermatol 1986; 15: 829-35
72. Brenner S, Wolf R, Dascalu DI. Topical tretinoin treatment in basal cell carcinoma. J Dermatol Surg Oncol 1993; 19: 264-6
73. Euvrard S, Verschoore M, Touraine JL. et al. Topical retinoids for warts and keratoses in transplant recipients. Lancet 1992; 340: 48-9
74. Marcusson JA, Tyden P. Acne conglobata in transplant patients treated with isotretinoin. Br J Dermatol 1988; 118: 310-2
75. Kiraly CL, Valkamo MH. Renal transplantation and isotretinoin. Acta Derm Venereol 1990; 70: 540
76. Abel B. Isotretinoin treatment of severe cystic acne in a heart transplant patient receiving cyclosporine: consideration of drug interactions. J Am Acad Dermatol 1991; 24: 511
77. Bunker CB, Rustin MHA, Dowd PM. Isotretinoin treatment of severe acne in posttransplant patients taking cyclosporine. J Am Acad Dermatol 1990; 22: 693-4